{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023246","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.690945+00:00","generated_at":"2026-06-22T04:31:30.289277+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LifeStance Q3 rev +25% to $217.6M; cuts FY22 guidance on lower visits, higher health costs; CEO/CFO changes","bullets":["Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).","Full-year 2022 guidance lowered: revenue $845-850M, Center Margin $229-232M, Adjusted EBITDA $50-53M.","Ken Burdick appointed Chairman & CEO effective Sept 7, succeeding Michael Lester (remains strategic advisor).","CFO transition: J. Michael Bruff to Business Transformation Officer; David Bourdon to become CFO Nov 10.","Ended Q3 with $90.3M cash, $212.0M net debt; total clinicians 5,431 (+24% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023246","json":"https://secwatch.observer/filing/0000950170-22-023246.json","markdown":"https://secwatch.observer/filing/0000950170-22-023246.md","text":"https://secwatch.observer/filing/0000950170-22-023246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/0000950170-22-023246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/lfst-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:31:30.289277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7aefc7493ce31bd3292103f96e528ebafc0e3a17","claim":"LifeStance Health Group, Inc. reported the quarter ended September 30, 2022 results: revenue $217.6 million, net income Net loss of $37.9 million. Guidance reaffirmed.","evidence_excerpt":"for the quarter ended September 30, 2022. (All results compared to prior-year comparative period, unless otherwise noted) Q3 2022 Highlights and FY 2022 Outlook • Revenue of $217.6 million increased $43.8 million or 25% compared to revenue of $173.8 million • Total clinicians of 5,431 up 24%, a net increase of 205 in the third quarter • Net loss of $37.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845257/000095017022023246/0000950170-22-023246-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$217.6 million"},{"label":"Net income","value":"Net loss of $37.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}